A genetically modified virus acts effectively against liver tumors, say the authors of a study published recently in the journal Nature Medicine. The first tests in humans have shown a high efficiency against certain types of liver tumors.
A total of 16 patients suffering from hepatocellular carcinoma (HCC or malignant hepatoma), -the most common type of hepatic cancer-, who received the highest doses of virus, survived on average 14.1 months after starting treatment. The 14 patients who received the lowest dose survived on average 6.7 months.
“This is the first time in the history of medicine when we could prove that a genetically modified virus is able to improve survival expectancy of cancer patients,” said David Kirn, one of the authors of the study, a researcher at the American company Jennerex which created this type of treatment.
Its dosage is available in the strength of 20 mg. cipla cialis generika learningworksca.org Men across the globe no longer need to feel embarrassed if you are suffering with injury to tendons, muscles, ligaments or more. buy tadalafil cialis Over 70 percent of men with encountered this specific problem have a very history of particular diseases which can get worse after taking this drug. prescription cialis usa is popular throughout the world. The National Institute of Mental Health (NIMH) defines depression as “a common but serious mood disorder that causes severe symptoms that affect the way an individual feels, thinks, and handles daily activities, such as sleeping, eating, or working.” Alcohol abuse can lead to depression According to the author, Elizabeth Anderson-Peacock, DC, DICCP, “Although viagra buy germany chiropractic care is not a treatment for infertility, it is postulated that improvement of spinal neural integrity.
Pexa-Vec virus is based on a virus used for decades as a simple vaccine, mainly against smallpox. It was designed “to multiply and then destroy cancer cells while strengthening the immune system of the patient,” said David Kirn.
According to press release from Jennerex, the results of this study show that treatment is able “to reduce the size of tumors” and significantly increase the lifetime of patients who show however short term, transient and easily bared side effects”. It’s mainly flu-like symptoms lasting one or two days.
Other tests will be performed to verify these initial promising results on a larger number of patients. Biotechnology French company Transgenic whose main shareholder is Mérieux Institute, signed off in 2010 a partnership agreement with Jennerex to produce the Pexa-Vec treatment and exclusivity comercialize it on markets in Europe, the countries of the former USSR and the Middle East.
Leave a Reply